Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Expels Kaketsuken over GMP Violations, Cover-Up
January 22, 2016
- PhRMA Japan Representative Ira Wolf Dies at 70
January 19, 2016
- JPMA Head Hints “Free Pricing” Could Be an Option in System Overhaul
January 18, 2016
- JPMA Unveils Pharma Industry Vision 2025
January 18, 2016
- PhRMA Picks Amy Jackson as New Japan Representative
January 15, 2016
- Mandatory Cancer Registration Gets Underway in Japan
January 14, 2016
- JGA Takes Sincerely 50% Pricing Rule for First Generics, There’s Limitation to Data Collection: Chief
January 13, 2016
- EFPIA Japan Chief Raps Huge Seller Re-Pricing, Says April Reform Will Chill the Market
January 8, 2016
- April Drug Price Revision “Will Be a Hard One” for the Industry: Pharma Leader Nakayama
January 7, 2016
- JPWA President Expresses Opposition to Market Price Survey in Conjunction with Sales Tax Hike, Calls for “Simplified Survey” If Necessary
January 6, 2016
- JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
- Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
- FPMAJ Chief Says It’s Time for Social Security Overhaul, Sub-Optimization Has Reached Limit
January 5, 2016
- Special Re-Pricing of Huge-Seller Drugs “Unacceptable,” JPMA Says on FY2016 Reform
December 25, 2015
- JPWA to Establish Taskforce to Discuss Measures for Distribution Problems Cited in Ryukaikon’s New Proposal
December 24, 2015
- JPMA Reprimands Novartis over Side Effect Reporting Violation
December 18, 2015
- JPMA to Watch Regulators’ Moves to Decide Its Action on Kaketsuken
December 18, 2015
- JPMA Says Re-Pricing of Huge-Seller Drugs Unreasonable, Preparing Statement
December 18, 2015
- Lilly’s Jonsson to Become Japan Chief of PhRMA
December 18, 2015
- PhRMA Sounds Alarm on “Huge Seller” Re-Pricing, Possible Decline in Japan Investment
December 14, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…